Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.

Lee EQ, Weller M, Sul J, Bagley SJ, Sahebjam S, van den Bent M, Ahluwalia M, Campian JL, Galanis E, Gilbert MR, Holdhoff M, Lesser GJ, Lieberman FS, Mehta MP, Penas-Prado M, Schreck KC, Strowd RE, Vogelbaum MA, Walbert T, Chang SM, Nabors LB, Grossman S, Reardon DA, Wen PY.

Neuro Oncol. 2020 Jan 24. pii: noaa015. doi: 10.1093/neuonc/noaa015. [Epub ahead of print]

PMID:
31974566
2.

An Update on Neurofibromatosis Type 1-Associated Gliomas.

Lobbous M, Bernstock JD, Coffee E, Friedman GK, Metrock LK, Chagoya G, Elsayed G, Nakano I, Hackney JR, Korf BR, Nabors LB.

Cancers (Basel). 2020 Jan 1;12(1). pii: E114. doi: 10.3390/cancers12010114. Review.

3.

Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma.

Creed JH, Peeri NC, Anic GM, Thompson RC, Olson JJ, LaRocca RV, Chowdhary SA, Brockman JD, Gerke TA, Nabors LB, Egan KM.

Sci Rep. 2019 Jul 26;9(1):10861. doi: 10.1038/s41598-019-47284-4.

4.

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.

Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Stupp R, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN.

Neuro Oncol. 2019 Dec 17;21(12):1498-1508. doi: 10.1093/neuonc/noz119.

PMID:
31276167
5.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY.

Neurosurgery. 2019 Sep 1;85(3):E607-E608. doi: 10.1093/neuros/nyz186. No abstract available.

PMID:
31215634
6.

Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study.

Fathallah-Shaykh HM, DeAtkine A, Coffee E, Khayat E, Bag AK, Han X, Warren PP, Bredel M, Fiveash J, Markert J, Bouaynaya N, Nabors LB.

PLoS Med. 2019 May 28;16(5):e1002810. doi: 10.1371/journal.pmed.1002810. eCollection 2019 May.

7.

Management of Central Nervous System Tumors.

Kaley T, Nabors LB.

J Natl Compr Canc Netw. 2019 May 1;17(5.5):579-582. doi: 10.6004/jnccn.2019.5012.

PMID:
31117044
8.

Anti-cancer effects of the HuR inhibitor, MS-444, in malignant glioma cells.

Wang J, Hjelmeland AB, Nabors LB, King PH.

Cancer Biol Ther. 2019;20(7):979-988. doi: 10.1080/15384047.2019.1591673. Epub 2019 Apr 16.

PMID:
30991885
9.

Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics.

Ostrom QT, Egan KM, Nabors LB, Gerke T, Thompson RC, Olson JJ, LaRocca R, Chowdhary S, Eckel-Passow JE, Armstrong G, Wiencke JK, Bernstein JL, Claus EB, Il'yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Sadetzki S, Schildkraut JM, Shete S, Houlston RS, Jenkins RB, Wrensch MR, Melin B, Amos CI, Huse JT, Barnholtz-Sloan JS, Bondy ML.

Int J Cancer. 2020 Feb 1;146(3):739-748. doi: 10.1002/ijc.32318. Epub 2019 Apr 22.

PMID:
30963577
10.

An early feasibility study of the Nativis Voyager® device in patients with recurrent glioblastoma: first cohort in US.

Cobbs C, McClay E, Duic JP, Nabors LB, Morgan Murray D, Kesari S.

CNS Oncol. 2019 Mar;8(1):CNS30. doi: 10.2217/cns-2018-0013. Epub 2018 Dec 14.

11.

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.

Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M.

Clin Cancer Res. 2019 Mar 15;25(6):1809-1816. doi: 10.1158/1078-0432.CCR-18-3181. Epub 2018 Dec 4.

PMID:
30514777
12.

Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment.

Filippova N, Yang X, An Z, Nabors LB, Pereboeva L.

J Cancer Sci Ther. 2018;10(8):190-197. doi: 10.4172/1948-5956.1000543. Epub 2018 Aug 6.

13.

Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma.

Blakeley JO, Grossman SA, Chi AS, Mikkelsen T, Rosenfeld MR, Ahluwalia MS, Nabors LB, Eichler A, Ribas IG, Desideri S, Ye X; Adult Brain Tumor Consortium.

Clin Cancer Res. 2019 Jan 1;25(1):73-79. doi: 10.1158/1078-0432.CCR-18-0110. Epub 2018 Aug 21.

14.

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.

Le Rhun E, Genbrugge E, Stupp R, Chinot OL, Nabors LB, Cloughesy T, Reardon DA, Wick W, Gorlia T, Weller M.

Eur J Cancer. 2018 Sep;101:95-104. doi: 10.1016/j.ejca.2018.06.029. Epub 2018 Jul 20.

PMID:
30036741
15.

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.

Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R.

Neuro Oncol. 2019 Jan 1;21(1):106-114. doi: 10.1093/neuonc/noy091.

16.

Toenail selenium, genetic variation in selenoenzymes and risk and outcome in glioma.

Peeri NC, Creed JH, Anic GM, Thompson RC, Olson JJ, LaRocca RV, Chowdhary SA, Brockman JD, Gerke TA, Nabors LB, Egan KM.

Cancer Epidemiol. 2018 Aug;55:45-51. doi: 10.1016/j.canep.2018.05.002. Epub 2018 May 25.

PMID:
29777993
17.

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

Happold C, Gorlia T, Nabors LB, Erridge SC, Reardon DA, Hicking C, Picard M, Stupp R, Weller M; EORTC Brain Tumor Group and on behalf of the CENTRIC and CORE Clinical Trial Groups.

J Neurooncol. 2018 May;138(1):163-171. doi: 10.1007/s11060-018-2786-8. Epub 2018 Feb 8.

PMID:
29423540
18.

Handedness and the risk of glioma.

Miller B, Peeri NC, Nabors LB, Creed JH, Thompson ZJ, Rozmeski CM, LaRocca RV, Chowdhary S, Olson JJ, Thompson RC, Egan KM.

J Neurooncol. 2018 May;137(3):639-644. doi: 10.1007/s11060-018-2759-y. Epub 2018 Jan 13.

19.

NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017.

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Butowski N, Fenstermaker RA, Forsyth P, Hattangadi-Gluth J, Holdhoff M, Howard S, Junck L, Kaley T, Kumthekar P, Loeffler JS, Moots PL, Mrugala MM, Nagpal S, Pandey M, Parney I, Peters K, Puduvalli VK, Ragsdale J, Rockhill J, Rogers L, Rusthoven C, Shonka N, Shrieve DC, Sills AK, Swinnen LJ, Tsien C, Weiss S, Wen PY, Willmarth N, Bergman MA, Engh A.

J Natl Compr Canc Netw. 2017 Nov;15(11):1331-1345. doi: 10.6004/jnccn.2017.0166.

PMID:
29118226
20.

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.

van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26.

21.

The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy.

Warren PP, Bebin EM, Nabors LB, Szaflarski JP.

Neurocase. 2017 Oct - Dec;23(5-6):287-291. doi: 10.1080/13554794.2017.1391294. Epub 2017 Oct 24.

PMID:
29063814
22.

Implementation and utilization of the molecular tumor board to guide precision medicine.

Harada S, Arend R, Dai Q, Levesque JA, Winokur TS, Guo R, Heslin MJ, Nabell L, Nabors LB, Limdi NA, Roth KA, Partridge EE, Siegal GP, Yang ES.

Oncotarget. 2017 Jun 14;8(34):57845-57854. doi: 10.18632/oncotarget.18471. eCollection 2017 Aug 22. Review.

23.

Hu antigen R (HuR) multimerization contributes to glioma disease progression.

Filippova N, Yang X, Ananthan S, Sorochinsky A, Hackney JR, Gentry Z, Bae S, King P, Nabors LB.

J Biol Chem. 2017 Oct 13;292(41):16999-17010. doi: 10.1074/jbc.M117.797878. Epub 2017 Aug 8.

24.

When less is better: care of the elderly with glioblastoma.

Nabors LB.

Neuro Oncol. 2017 Jul 1;19(7):879. doi: 10.1093/neuonc/nox075. No abstract available.

25.

Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.

Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, Lesser GJ, Read WL, Lieberman FS, Lodge MA, Leal J, Fisher JD, Desideri S, Grossman SA, Wahl RL, Schiff D.

Neuro Oncol. 2017 Jun 1;19(6):845-852. doi: 10.1093/neuonc/nox020.

26.

Older age at the completion of linear growth is associated with an increased risk of adult glioma.

Little RB, Nabors LB, Olson JJ, Thompson ZJ, Rozmeski CM, LaRocca RV, Forsyth PA, Thompson RC, Oster RA, Chowdhary SA, Egan KM.

Cancer Causes Control. 2017 Jul;28(7):709-716. doi: 10.1007/s10552-017-0871-5. Epub 2017 Mar 4. Erratum in: Cancer Causes Control. 2017 Jul;28(7):717-718.

27.

Primary Sellar Rhabdomyosarcoma Arising in Association With a Pituitary Adenoma.

Duncan VE, Nabors LB, Warren PP, Conry RM, Willey CD, Perry A, Riley KO, Hackney JR.

Int J Surg Pathol. 2016 Dec;24(8):753-756. Epub 2016 Jul 14.

PMID:
27422470
28.

Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma.

Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Mountz JM, Lieberman FS, Fisher JD, Desideri S, Ye X, Grossman SA, Schiff D, Wahl RL.

J Nucl Med. 2017 Mar;58(3):393-398. doi: 10.2967/jnumed.116.178434. Epub 2016 Sep 29.

29.

Pilot Study to Explore the Accuracy of Current Prediction Equations in Assessing Energy Needs of Patients with Newly Diagnosed Glioblastoma Multiforme.

Little RB, Oster RA, Darnell BE, Demark-Wahnefried W, Nabors LB.

Nutr Cancer. 2016 Aug-Sep;68(6):926-34. doi: 10.1080/01635581.2016.1187279. Epub 2016 Jun 24.

30.
31.

Reply to F. Felix et al and M.F. Fay et al.

Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M.

J Clin Oncol. 2016 Sep 1;34(25):3107-8. doi: 10.1200/JCO.2016.68.0926. Epub 2016 Jun 13. No abstract available.

32.

Central Nervous System: Notable Developments in the Management of Primary and Recurrent Gliomas.

Nabors LB.

J Natl Compr Canc Netw. 2016 May;14(5 Suppl):681-4.

PMID:
27226514
33.

Complications from pharmacotherapy.

Nabors LB, Surboeck B, Grisold W.

Handb Clin Neurol. 2016;134:235-50. doi: 10.1016/B978-0-12-802997-8.00014-1. Review.

PMID:
26948358
34.

Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.

Weller M, Nabors LB, Gorlia T, Leske H, Rushing E, Bady P, Hicking C, Perry J, Hong YK, Roth P, Wick W, Goodman SL, Hegi ME, Picard M, Moch H, Straub J, Stupp R.

Oncotarget. 2016 Mar 22;7(12):15018-32. doi: 10.18632/oncotarget.7588.

35.

Analgesic use and the risk of primary adult brain tumor.

Egan KM, Nabors LB, Thompson ZJ, Rozmeski CM, Anic GA, Olson JJ, LaRocca RV, Chowdhary SA, Forsyth PA, Thompson RC.

Eur J Epidemiol. 2016 Sep;31(9):917-25. doi: 10.1007/s10654-016-0129-7. Epub 2016 Feb 19.

36.

Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.

Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M.

J Clin Oncol. 2016 Mar 1;34(7):731-9. doi: 10.1200/JCO.2015.63.6563. Epub 2016 Jan 19.

37.

Complementary therapy and survival in glioblastoma.

Mulpur BH, Nabors LB, Thompson RC, Olson JJ, LaRocca RV, Thompson Z, Egan KM.

Neurooncol Pract. 2015 Sep;2(3):122-126. Epub 2015 May 6.

38.

Central Nervous System Cancers, Version 1.2015.

Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM.

J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202.

PMID:
26483059
39.

Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.

Blakeley JO, Grossman SA, Mikkelsen T, Rosenfeld MR, Peereboom D, Nabors LB, Chi AS, Emmons G, Garcia Ribas I, Supko JG, Desideri S, Ye X.

J Neurooncol. 2015 Oct;125(1):123-31. doi: 10.1007/s11060-015-1876-0. Epub 2015 Aug 19.

40.

Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.

Gounder MM, Nayak L, Sahebjam S, Muzikansky A, Sanchez AJ, Desideri S, Ye X, Ivy SP, Nabors LB, Prados M, Grossman S, DeAngelis LM, Wen PY.

J Clin Oncol. 2015 Oct 1;33(28):3186-92. doi: 10.1200/JCO.2015.61.1525. Epub 2015 Aug 17.

41.

Cognitive Predictors of Reasoning through Treatment Decisions in Patients with Newly Diagnosed Brain Metastases.

Gerstenecker A, Duff K, Meneses K, Fiveash JB, Nabors LB, Triebel KL.

J Int Neuropsychol Soc. 2015 Jul;21(6):412-8. doi: 10.1017/S1355617715000478. Epub 2015 Jul 7.

42.

Impairment of medical decisional capacity in relation to Karnofsky Performance Status in adults with malignant brain tumor.

Martin RC, Gerstenecker A, Nabors LB, Marson DC, Triebel KL.

Neurooncol Pract. 2015 Mar;2(1):13-19. Epub 2014 Dec 4.

43.

Hypofractionated stereotactic radiosurgery with concurrent bevacizumab for recurrent malignant gliomas: the University of Alabama at Birmingham experience.

Clark GM, McDonald AM, Nabors LB, Fathalla-Shaykh H, Han X, Willey CD, Markert JM, Guthrie BL, Bredel M, Fiveash JB.

Neurooncol Pract. 2014 Dec;1(4):172-177.

44.

SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma.

Robert SM, Buckingham SC, Campbell SL, Robel S, Holt KT, Ogunrinu-Babarinde T, Warren PP, White DM, Reid MA, Eschbacher JM, Berens ME, Lahti AC, Nabors LB, Sontheimer H.

Sci Transl Med. 2015 May 27;7(289):289ra86. doi: 10.1126/scitranslmed.aaa8103.

45.

Ipilimumab-induced encephalopathy with a reversible splenial lesion.

Conry RM, Sullivan JC, Nabors LB 3rd.

Cancer Immunol Res. 2015 Jun;3(6):598-601. doi: 10.1158/2326-6066.CIR-15-0035. Epub 2015 Apr 28.

46.

Growth factor dependent regulation of centrosome function and genomic instability by HuR.

Filippova N, Yang X, Nabors LB.

Biomolecules. 2015 Mar 20;5(1):263-81. doi: 10.3390/biom5010263.

47.

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.

Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, Picard M, Hegi ME, Lhermitte B, Reardon DA.

Neuro Oncol. 2015 May;17(5):708-17. doi: 10.1093/neuonc/nou356. Epub 2015 Mar 11.

48.

Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas.

Bag AK, Kim H, Gao Y, Bolding M, Warren PP, Fathallah-Shaykh HM, Gurler D, Markert JM, Fiveash J, Beasley TM, Khawaja A, Friedman GK, Chapman PR, Nabors LB, Han X.

J Neurooncol. 2015 May;122(3):585-93. doi: 10.1007/s11060-015-1751-z. Epub 2015 Feb 25.

PMID:
25711673
49.

Capacity of patients with brain metastases to make treatment decisions.

Triebel KL, Gerstenecker A, Meneses K, Fiveash JB, Meyers CA, Cutter G, Marson DC, Martin RC, Eakin A, Watts O, Nabors LB.

Psychooncology. 2015 Nov;24(11):1448-55. doi: 10.1002/pon.3753. Epub 2015 Jan 23.

50.

Role of MRI in primary brain tumor evaluation.

Leung D, Han X, Mikkelsen T, Nabors LB.

J Natl Compr Canc Netw. 2014 Nov;12(11):1561-8. Review.

PMID:
25361803

Supplemental Content

Loading ...
Support Center